These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 27129065)

  • 1. Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
    Linnemann B; Erbe M
    Vasa; 2016; 45(3):201-12. PubMed ID: 27129065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic literature review to inform the Portuguese recommendations for the management of Raynaud's phenomenon and digital ulcers in systemic sclerosis and other connective tissue diseases.
    Costa E; Cunha-Santos F; Dourado E; Oliveira D; Falzon L; Romão V; Duarte AC; Cordeiro A; Santiago T; Sepriano A
    ARP Rheumatol; 2024 Jul; 3(Apr-Jun):128-144. PubMed ID: 38306796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnosis and treatment of Raynaud's phenomenon: a practical approach.
    Pope JE
    Drugs; 2007; 67(4):517-25. PubMed ID: 17352512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary management of Raynaud's phenomenon and digital ischaemic complications.
    Herrick AL
    Curr Opin Rheumatol; 2011 Nov; 23(6):555-61. PubMed ID: 21885977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Raynaud's syndrome, 2011].
    Takáts A; Garai I; Papp G; Hevér T; Csiki E; András C; Csiki Z
    Orv Hetil; 2012 Mar; 153(11):403-9. PubMed ID: 22390864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.
    Lee EY; Park JK; Lee W; Kim YK; Park CS; Giles JT; Park JW; Shin K; Lee JS; Song YW; Lee EB
    Rheumatology (Oxford); 2014 Apr; 53(4):658-64. PubMed ID: 24352340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic management of acral manifestations of systemic sclerosis].
    Meyer MF; Daigeler A; Lehnhardt M; Steinau HU; Klein HH
    Med Klin (Munich); 2007 Mar; 102(3):209-18. PubMed ID: 17345017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raynaud, digital ulcers and calcinosis in scleroderma.
    Nitsche A
    Reumatol Clin; 2012; 8(5):270-7. PubMed ID: 22835924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Part II: The treatment of primary and secondary Raynaud's phenomenon.
    Curtiss P; Svigos K; Schwager Z; Lo Sicco K; Franks AG
    J Am Acad Dermatol; 2024 Feb; 90(2):237-248. PubMed ID: 35809802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
    Botzoris V; Drosos AA
    Joint Bone Spine; 2011 Jul; 78(4):341-6. PubMed ID: 21183379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ulnar artery involvement in systemic sclerosis (scleroderma).
    Taylor MH; McFadden JA; Bolster MB; Silver RM
    J Rheumatol; 2002 Jan; 29(1):102-6. PubMed ID: 11824945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
    Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
    Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Raynaud's phenomenon.
    García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Pardo-Santos R; Levy R; Maldonado CG; Chávez GP; Cervera R
    Autoimmun Rev; 2008 Oct; 8(1):62-8. PubMed ID: 18692160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raynaud's phenomenon: Current concepts.
    Stringer T; Femia AN
    Clin Dermatol; 2018; 36(4):498-507. PubMed ID: 30047433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raynaud's phenomenon-an update on diagnosis, classification and management.
    Pauling JD; Hughes M; Pope JE
    Clin Rheumatol; 2019 Dec; 38(12):3317-3330. PubMed ID: 31420815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raynaud's Syndrome: a neglected disease.
    Poredos P; Poredos P
    Int Angiol; 2016 Apr; 35(2):117-21. PubMed ID: 25673314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.